Related Experiment Video
Updated: Nov 4, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer
Amanda N Lisby1, John C Flickinger1, Babar Bashir2
1Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, United States.
Introduction:
Colorectal cancer (CRC) is one of the most-deadly malignancies worldwide. Current therapeutic regimens for CRC patients are relatively generic, based primarily on disease type and stage, with little variation. As the field of molecular oncology advances, so too must therapeutic management of CRC. Understanding molecular heterogeneity has led to a new-found promotion for precision therapy in CRC; underlining the diversity of molecularly targeted therapies based on individual tumor characteristics.
Areas Covered:
We review current approaches for the treatment of CRC and discuss the potential of precision therapy in advanced CRC. We highlight the utility of the intestinal protein guanylyl cyclase C (GUCY2C), as a multi-purpose biomarker and unique therapeutic target in CRC. Here, we summarize current GUCY2C-targeted approaches for treatment of CRC.
Expert Opinion:
The GUCY2C biomarker has multi-faceted utility in medicine. Developmental investment of GUCY2C as a diagnostic and therapeutic biomarker offers a variety of options taking the molecular characteristics of cancer into account. From GUCY2C-targeted therapies, namely cancer vaccines, CAR-T cells, and monoclonal antibodies, to GUCY2C agonists for chemoprevention in those who are at high risk for developing colorectal cancer, the utility of this protein provides many avenues for exploration with significance in the field of precision medicine.
Insights
Precision therapy for colorectal cancer (CRC) is advancing. Guanylyl cyclase C (GUCY2C) shows promise as a biomarker and therapeutic target for personalized CRC treatment strategies.
Area of Science:
- Oncology
- Molecular Oncology
- Precision Medicine
Background:
- Colorectal cancer (CRC) is a leading cause of cancer mortality globally.
- Current CRC treatments are largely non-specific, lacking personalization.
- Advances in molecular oncology necessitate tailored therapeutic approaches for CRC.
Purpose of the Study:
- To review current colorectal cancer (CRC) treatments.
- To explore the potential of precision therapy in advanced CRC.
- To highlight guanylyl cyclase C (GUCY2C) as a biomarker and therapeutic target.
Main Methods:
- Literature review of CRC treatment approaches.
- Analysis of precision therapy strategies in advanced CRC.
- Summary of GUCY2C-targeted therapeutic modalities.
Main Results:
- Guanylyl cyclase C (GUCY2C) demonstrates significant utility as a biomarker.
- GUCY2C serves as a unique therapeutic target in colorectal cancer.
- GUCY2C-targeted therapies offer diverse treatment options.
Conclusions:
- GUCY2C possesses multifaceted utility in medical applications.
- Developing GUCY2C as a diagnostic and therapeutic biomarker supports personalized medicine.
- GUCY2C-targeted therapies, including vaccines and CAR-T cells, alongside agonists for chemoprevention, represent promising avenues in precision oncology.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
15:17Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
